Activation of FGFR-signaling mediates resistance of gastrointestinal stromal tumors (GISTs) to imatinib (IM)

被引：0
|
作者：
Garanina, E. [1 ]
Boichuk, S. [2 ]
Dunaev, P. [2 ]
Galembikova, A. [2 ]
Shagimardanova, E. [1 ]
Gusev, O. [1 ]
Khaiboullina, S. [1 ]
机构：
[1] Kazan Fed Univ, Kazan, Russia
[2] Kazan State Med Univ, Kazan, Russia
来源：
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION | 2018年 / 48卷
基金：
俄罗斯科学基金会;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P071-F
引用
收藏
页码：159 / 159
页数：1
相关论文
共 50 条
  • [1] Targeting of FGFR-Signaling enhances sensitivity of Gastrointestinal Stromal Tumors (GIST) to Imatinib (IM).
    Boichuk, S.
    Dunaev, P.
    Galembikova, A.
    Micheeva, E.
    Valeeva, E.
    Novikova, M.
    Khromova, N.
    Kopnin, P.
    Rizvanov, A.
    MOLECULAR BIOLOGY OF THE CELL, 2018, 29 (26)
  • [2] Evaluation of imatinib mesylate (IM) in patients with large volume gastrointestinal stromal tumors (GISTs)
    Byrd, D. M.
    Demetri, G. D.
    Joensuu, H.
    von Mehren, M.
    Heinrich, M.
    Eisenberg, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Does imatinib mesylate (IM) affect longterm outcome in patients with gastrointestinal stromal tumors (GISTs)?
    Jin, Judy
    Robinson, Ann
    Willis, Joseph
    Hardacre, Jeffrey
    Kim, Julian
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 205 (03) : S14 - S14
  • [4] Imatinib discontinuation in patients with metastatic gastrointestinal stromal tumors (GISTs)
    de Pas, Tommaso
    Biffi, Roberto
    Mazzarol, Giovanni
    Della Vigna, Paolo
    Travaini, Laura
    Curigliano, Giuseppe
    Formica, Vincenzo
    de Braud, Filippo
    ANNALS OF ONCOLOGY, 2004, 15 : 201 - 201
  • [5] Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
    Quek, Richard
    George, Suzanne
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 19 - 31
  • [6] Imatinib mesylate (IM) promotes malignant behaviour of IM-resistant gastrointestinal stromal tumours (GISTs) via activation of FGF-signaling
    Boichuk, S.
    Mikheeva, E.
    Sabirov, A.
    Petrov, S.
    Novikova, M.
    Kopnin, P.
    Valeeva, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S1230 - S1230
  • [7] Imatinib resistance in gastrointestinal stromal tumors
    Chen L.L.
    Sabripour M.
    Andtbacka R.H.I.
    Patel S.R.
    Feig B.W.
    Macapinlac H.A.
    Choi H.
    Wu E.F.
    Frazier M.L.
    Benjamin R.S.
    Current Oncology Reports, 2005, 7 (4) : 293 - 299
  • [8] The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib
    Di Vito, Aldo
    Ravegnini, Gloria
    Gorini, Francesca
    Aasen, Trond
    Serrano, Cesar
    Benuzzi, Eva
    Coschina, Emma
    Monesmith, Sarah
    Morroni, Fabiana
    Angelini, Sabrina
    Hrelia, Patrizia
    PHARMACOLOGY & THERAPEUTICS, 2023, 248
  • [9] Molecular heterogeneity of imatinib resistance in GI stromal tumors (GISTs)
    Kepten, Ilana
    Liegl-Atzwanger, Bernadette
    Le, Claudia
    Fletcher, Christopher
    Heinrich, Michael
    Fletcher, Jonathan
    Corless, Christopher
    CANCER RESEARCH, 2008, 68 (09)
  • [10] Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)-review and perspectives
    Laurent, Marie
    Brahmi, Mehdi
    Dufresne, Armelle
    Meeus, Pierre
    Karanian, Marie
    Ray-Coquard, Isabelle
    Blay, Jean-Yves
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 4
12345